摘要
疏血通注射液是第1个动物类中药注射剂,主要成分为水蛭、地龙,拥有5项国家发明专利,是公认最强效的中药破血逐瘀剂,也是SFDA批准的药品说明书适应症中唯一明确为脑梗死急性期,临床应用最广泛的急重症抢救中药。其采用了现代生物提取技术制备,整个生产过程中仅采用生理盐水作为溶剂。采用专利工艺,最大限度地保留药效成分和活性,同时去除无效物质和易引起过敏反应的异体蛋白、大相对分子质量物质。物质基础研究已分离、鉴定出疏血通注射液中7类共56种单体化合物,相对分子质量100～1 700,主要包括多肽、糖肽、内源性小分子等。
Shuxuetong （SXT） injection is the first animal original injection in traditional Chinese medicine, the main component are the leech and the earthworm. SXT has got five national invention patents, and is recognized as the most potent medicine expelling blood stasis agent, which indication is the only one be clearly approved by SFDA as the acute phase of cerebral infarction. Modern biological extraction technology is adopted to prepare SXT, the entire production process using only saline as a solvent. Patented product process is induced to maximize the retention of medicinal components and activity, as well as to remove invalid substances as vari- ant protein, high molecular weight substances which causes allergic reactions. SXT have been isolated and identified class 7 of 56 compounds, the molecular weight is from 100 to 1 700 Da, mainly including peptides, glycopeptides, endogenous small molecules.
出处
《中国中药杂志》
CAS
CSCD
北大核心
2012年第18期2818-2819,共2页
China Journal of Chinese Materia Medica
基金
国家"重大新药创制"科技重大专项(2009ZX09502-030)"中药上市后评价关键技术研究"
关键词
疏血通注射液
质量标准
工艺
物质基础
安全性
Shuxuetong injection
quality standards
process
material basis
safety
